# EDGAR Filing Document

**Accession Number:** 0001861657
**File Stem:** 0001493152-25-027223
**Filing Date:** 2025-12
**Character Count:** 2481
**Document Hash:** 907359fee9adea033e26fb215d9e5744
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-027223.hdr.sgml**: 20260608

**ACCESSION NUMBER**: 0001493152-25-027223

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251211

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tharimmune, Inc.
- **CENTRAL INDEX KEY:** 0001861657
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 842642541
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 1200 ROUTE 22 EAST
- **CITY:** BRIDGEWATER
- **STATE:** NJ
- **ZIP:** 08807
- **BUSINESS PHONE:** 302-743-2995

**MAIL ADDRESS:**
- **STREET 1:** 34 SHREWSBURY AVE
- **STREET 2:** SUITE 1C
- **CITY:** RED BANK
- **STATE:** NJ
- **ZIP:** 07701

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Tharimmune, Inc.
- **DATE OF NAME CHANGE:** 20230925

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Tharimmune, Inc
- **DATE OF NAME CHANGE:** 20230925

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Hillstream BioPharma Inc.
- **DATE OF NAME CHANGE:** 20210511

**THARIMMUNE, INC.** 

**34 Shrewsbury Ave., Suite 1C**

**Red Bank, NJ** 

December 11, 2025

**<u>VIA EDGAR</u>**

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

---

| | |
|:---|:---|
| **Re:** | **Tharimmune, Inc.** <br> **Registration Statement on Form S-3 (File No. 333-291975)** |

---

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Tharimmune, Inc. (the "**Company**") hereby requests that the effective date of the Company's Registration Statement on Form S-3 (File No. 333-291975) filed with the U.S. Securities and Exchange Commission on December 5, 2025 (the "**Registration Statement**"), be accelerated so that the Registration Statement will become effective on December 16, 2025, at 4:00 p.m., Eastern Standard Time, or as soon as practicable thereafter.

Please contact Ms. Yuta N. Delarck: of Reed Smith LLP at 212.549.0223 with any questions and please notify her by telephone when this request for acceleration has been granted.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| **Tharimmune, Inc** | **Tharimmune, Inc** |
| By: | */s/ Mark Wendland* |
|  | Mark Wendland<br> Chief Executive Officer |

---

cc: Yuta N. Delarck, Reed Smith LLP